) search for a partner to market its only approved product Afrezza
ended with the company inking a global licensing deal with French
company Sanofi (
). Afrezza was cleared by the FDA in Jun 2014 for the improvement
of glycemic control in adults suffering from diabetes mellitus.
According to the deal inked by MannKind on the diabetes product,
Sanofi will be responsible for commercial, regulatory and
development activities pertaining to Afrezza across the globe. The
companies also inked a supply agreement according to which MannKind
will manufacture Afrezza at its manufacturing facility in Danbury,
CT. Moreover, the companies intend to expand manufacturing capacity
of the diabetes drug to satisfy its worldwide demand.
The deal will boost MannKind's balance sheet substantially. The
U.S. based company will receive an upfront payment of $150 million
under the deal. Furthermore, MannKind is eligible to receive
milestone payments of up to $775 million. MannKind is eligible to
receive 35% of the global profits/losses emanating from Afrezza
sales. Sanofi will get the balance. Under the terms of the deal,
Sanofi will advance to MannKind its share of the partnership's
expenses of up to $175 million.
We are positive on MannKind's decision to choose a large and
experienced company like Sanofi as a partner for Afrezza. Shares of
MannKind were positively impacted by the news.
We believe the choice has been well made as Sanofi has
significant experience in marketing diabetes products. Sanofi's
marketing muscle should go a long way in making the U.S. launch
(expected in the first quarter of 2015) of MannKind's first
approved product a success. The deal will also result in a
substantial inflow of cash at MannKind. We expect investor
focus to remain on the performance of Afrezza following its launch.
Both MannKind and Sanofi are Zacks Rank #3 (Hold) companies.
Better-ranked stocks in the health care sector include Gilead
) and Actelion (
). Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MANNKIND CORP (MNKD): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
To read this article on Zacks.com click here.